ticlopidine-1a pharma 250 mg tabletki powlekane
1a pharma gmbh - ticlopidini hydrochloridum - tabletki powlekane - 250 mg
ifapidin 250 mg tabletki powlekane
egis pharmaceuticals ltd. - ticlopidini hydrochloridum - tabletki powlekane - 250 mg
aclotin 250 mg tabletki powlekane
bausch health ireland ltd. - ticlopidini hydrochloridum - tabletki powlekane - 250 mg
ticlo 250 mg tabletki powlekane
vedim sp. z o.o. - ticlopidini hydrochloridum - tabletki powlekane - 250 mg
apo-clodin 250 mg tabletki powlekane
apotex europe b.v. - ticlopidini hydrochloridum - tabletki powlekane - 250 mg
iclopid 250 mg tabletki powlekane
pabianickie zakłady farmaceutyczne polfa s.a. - ticlopidini hydrochloridum - tabletki powlekane - 250 mg
aspirin pro 500 mg tabletki powlekane
bayer sp. z o.o. - acidum acetylsalicylicum - tabletki powlekane - 500 mg
flexyess 0,02 mg + 3 mg tabletki powlekane
bayer pharma ag - ethinylestradiolum; drospirenonum - tabletki powlekane - 0,02 mg + 3 mg
okitask 25 mg tabletki powlekane
dompe farmaceutici s.p.a. - ketoprofenum lysinum - tabletki powlekane - 25 mg
rivaroxaban accord
accord healthcare s.l.u. - rywaroksaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - Środki przeciwzakrzepowe - profilaktyka żylnej choroby zakrzepowo-zatorowej (Żchzz) u dorosłych pacjentów poddawanych planowej operacji wymiany stawu biodrowego lub kolanowego. leczenie zakrzepicy żył głębokich (dvt) i zatorowości płucnej (ТЭЛА) i zapobiegania nawrotom zakrzepicy żył głębokich i ТЭЛА u dorosłych. (see section 4. 4 for haemodynamically unstable pe patients. leczenie zakrzepicy żył głębokich (dvt) i zatorowości płucnej (ТЭЛА) i zapobiegania nawrotom zakrzepicy żył głębokich i ТЭЛА u dorosłych. (see section 4. 4 hemodynamicznie niestabilna ТЭЛА pacjentów). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. leczenie zakrzepicy żył głębokich (dvt) i zatorowości płucnej (ТЭЛА) i zapobiegania nawrotom zakrzepicy żył głębokich i ТЭЛА u dorosłych. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 i 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. leczenie zakrzepicy żył głębokich (dvt) i zatorowości płucnej (ТЭЛА) i zapobiegania nawrotom zakrzepicy żył głębokich i ТЭЛА u dorosłych. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.